Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia
Haematologica. 2024 Feb 22.
doi: 10.3324/haematol.2023.284346.
Online ahead of print.
1 Department of Internal Medicine V, Heidelberg University Hospital.
2 Institute of Medical Biometry, University of Heidelberg.
3 NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center.
4 Department of Medicine IV, Aachen University Hospital, Aachen.
5 Department of Hematology, Oncology and Palliative Medicine, Community Hospital Bielefeld.
6 NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Germany; Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University; Department of Medicine I - Hematology and Cell Therapy, University Hospital Leipzig.
7 Department of Medicine V, Erlangen University Hospital.
8 Department of Medicine A, Münster University Hospital.
9 Department of Hematology and Oncology, St. Josef Brothers' Hospital Paderborn.
10 Department of Hematology, Oncology and Palliative Medicine, Robert-Bosch Hospital Stuttgart.
11 Department of Internal Medicine, Hematology, Oncology and Palliative Medicine, Prot. Monastery Hospital St. Jakob Koblenz.
12 Department of Hematology, Oncology and Palliative Medicine, Winnenden Hospital, Winnenden.
13 Department of Internal Medicine III - Hematology and Oncology, Red Cross Hospital Munich, Munich.
14 Department of Medicine I - Hematology and Cell Therapy, University Hospital Leipzig.
15 Department of Internal Medicine V, Heidelberg University Hospital, Germany; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center.